Canada markets open in 3 hours 33 minutes

WuXi Biologics (Cayman) Inc. (2269.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
79.700-5.850 (-6.84%)
At close: 04:08PM HKT
Full screen
Previous Close85.550
Open84.700
Bid79.650 x 0
Ask79.700 x 0
Day's Range78.900 - 85.050
52 Week Range72.100 - 148.000
Volume25,695,319
Avg. Volume21,255,179
Market Cap332.364B
Beta (5Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug. 23, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est158.25
  • Bloomberg

    U.S. to Blacklist DJI and Seven Other China Firms, FT Reports

    (Bloomberg) -- Shares of China’s biggest chipmaker and several of its largest pharmaceutical firms sank on Wednesday on fears that Washington will slap investment and export sanctions against more companies. Most Read from BloombergSouth Africa Hospitalization Rate Plunges in Omicron WaveBiden to Issue ‘Stark Warning’ on Vaccination Amid Covid SurgeEngland Has Hundreds of Thousands of New Omicron Cases DailyVaccine Data Gaps Point to Millions More in U.S. Who Lack ShotsThe Five-Day Office Week I

  • CNW Group

    WuXi Biologics Launches a New GMP Commercial Drug Product Facility

    WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced it has successfully launched the GMP operation of its new drug product facility located in Wuxi, China, which is the eighth operational drug product facility in the global network of WuXi Biologics.

  • Business Wire

    Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

    Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics ("WuXi Bio") (2269.HK) today announced the companies have entered into an exclusive license agreement to support the continued expansion of Exelixis’ oncology biologics pipeline. The agreement is the latest in a series of biologics-focused transactions for Exelixis as the company builds out its pipeline behind CABOMETYX® (cabozantinib), its flagship product and global oncology franchise, which received its fourth approval from the U.S. Food and Drug Administration in January.